1. Home
  2. Analysis
  3. Ambrisentan
  4. Facial-paralysis

Ambrisentan and Facial paralysis - a phase IV clinical study of FDA data

Summary:

Facial paralysis is reported as a side effect among people who take Ambrisentan (ambrisentan), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Adcirca, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Facial paralysis when taking Ambrisentan. It is created by eHealthMe based on reports of 61,294 people who have side effects when taking Ambrisentan from the FDA, and is updated regularly.

What is Ambrisentan?

Ambrisentan has active ingredients of ambrisentan. eHealthMe is studying from 61,368 Ambrisentan users. Check the latest studies of Ambrisentan.

What is Facial paralysis?

Facial paralysis (loss of function of face muscle) is found to be associated with 663 drugs and 1,149 conditions by eHealthMe. Check the latest studies of Facial paralysis.

On Jul, 21, 2026

61,294 people reported to have side effects when taking Ambrisentan.
Among them, 16 people (0.03%) have Facial paralysis.

Could Ambrisentan cause Facial paralysis?

Among these 16 people:

How long have people been on Ambrisentan when they have Facial paralysis? *

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Facial paralysis when taking Ambrisentan? *

  • female: 75 %
  • male: 25 %

What is the age of people who have Facial paralysis when taking Ambrisentan? *

  • 0-1: 0.0 %
  • 2-9: 8.33 %
  • 10-19: 0.0 %
  • 20-29: 25.0 %
  • 30-39: 8.33 %
  • 40-49: 8.33 %
  • 50-59: 8.33 %
  • 60+: 41.67 %

What are other drugs people take besides Ambrisentan? *

  1. Uptravi: 5 people, 31.25%
  2. Adcirca: 5 people, 31.25%
  3. Adempas: 3 people, 18.75%
  4. Remodulin: 2 people, 12.50%
  5. Orenitram: 2 people, 12.50%
  6. Eliquis: 2 people, 12.50%
  7. Cellcept: 2 people, 12.50%
  8. Tyvaso: 1 person, 6.25%
  9. Restasis: 1 person, 6.25%
  10. Proair Hfa: 1 person, 6.25%

What are other side effects people have besides Facial paralysis? *

  1. Diarrhea: 4 people, 25.00%
  2. Headache (pain in head): 3 people, 18.75%
  3. Hypoaesthesia (reduced sense of touch or sensation): 3 people, 18.75%
  4. Nausea (feeling of having an urge to vomit): 3 people, 18.75%
  5. Dizziness: 3 people, 18.75%
  6. Constipation: 2 people, 12.50%
  7. Dyspnea (difficult or laboured breathing): 2 people, 12.50%
  8. Drooling (drop saliva uncontrollably from the mouth): 1 person, 6.25%
  9. Gastric Disorder (disease of stomach): 1 person, 6.25%
  10. Fatigue (feeling of tiredness): 1 person, 6.25%

What are the existing conditions these people have? *

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 10 people, 62.50%
  2. Pulmonary Hypertension (increase in blood pressure in the lung artery): 5 people, 31.25%

* Approximation only. Some reports may have incomplete information.

Do you take Ambrisentan and have Facial paralysis?

- Check whether Facial paralysis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ambrisentan:

Facial paralysis treatments and more:

How severe was Facial paralysis and when was it recovered:

Expand to all the drugs that have ingredients of ambrisentan:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ambrisentan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Facial paralysis:

Browse all the conditions that are associated with Facial paralysis:

How the study uses the data?

The study uses data from the FDA. It is based on ambrisentan (the active ingredients of Ambrisentan) and Ambrisentan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.